Mpox Resource Center

In light of the recent cases of mpox in the U.S., the National Coalition for LGBTQ Health has curated a library of evidence-based materials in multiple formats about mpox. Geared to clinicians, researchers, and community members, the resources provide information about mpox virus transmission, prevention, testing, and treatment.   

Resources from CDC

Scientists at the Centers for Disease Control and Prevention (CDC) are tracking multiple cases of monkeypox that have been reported in several countries that don’t normally report mpox, including the United States.

It’s not clear how the people were exposed to mpox, but early data suggest that gay, bisexual, and other men who have sex with men make up a high number of cases. However, anyone who has been in close contact with someone who has mpox is at risk. CDC is urging healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox, regardless of whether they have travel or specific risk factors for mypox and regardless of gender or sexual orientation.

CDC is working with state and local health officials to identify people who may have been in contact with individuals who have tested positive for mpox, so they can monitor their health.

New and Updated

NIH: Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Study highlights need for defined markers of mpox immunity to inform public health use.

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.

Evidence-based interventions are needed to respond to current and future mpox outbreaks within and beyond the United States. To help meet domestic and international mpox response goals, CDC is urging clinicians to let patients with mpox know that oral tecovirimat is available through STOMP and encourage them to enroll. Providers should inform patients about STOMP so they can consider enrolling in the study. However, enrollment in the study is voluntary, and patients who decline to take part, or who do not meet the criteria to participate, can still obtain tecovirimat if recommended. For more information about obtaining TPOXX or about the STOMP study, visit or   

Potential Risk for New Mpox Cases: CDC Health Alert Network
In the United States, cases of mpox (formerly monkeypox) have declined since peaking in August 2022, but the outbreak is not over. The CDC continues to receive reports of cases that reflect ongoing community transmission in the United States and internationally.

Information for Healthcare Providers: Tecovirimat (TPOXX) and Guidance for Tecovirimat Use pages are now live.

CDC released a new MMWR highlighting shortfalls in progress toward equitable mpox vaccination coverage. Notably, as of April 2023, two thirds of mpox vaccine-eligible persons remain unvaccinated, and the shortfall was greatest among Black and AI/AN persons. 

Digital/Printable Resource: Protect Your Sexual Health: Tips for the LGBTQ+ Community palm card.

What treatments are available for mpox?

Clinician Fact Sheet: Virologic and Immunologic Characteristics of Severe Mpox in Persons with Advanced HIV (VIRISMAP)

How long can mpox survive on clothing and surfaces?

JYNNEOS Vaccine Coverage by Jurisdiction

Mpox Vaccination Basics

Treatment Information for Healthcare Professionals

What is intradermal administration of the JYNNEOS vaccine?

Risk of Mpox Resurgence and Continued Vaccination Efforts

Stay current on CDC’s mpox resources online by visiting the What’s New & Updated page.

Advisory Committee on Immunization Practices (ACIP) Meeting, Feb. 22-24, 2023
If You Are Sick
Funding Resources
Health Departments
Data and Analytics
Additional CDC Resources
Partner ReSources
Copyright © 2024 National Coalition for LGBTQ Health | All rights reserved.